Update: The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline
rg . ...For this Initiative IDRI is providing substantial expertise inmicrob...(Logo: A HREF http://www.newscom.com/cgi-bin/prnh/20081007/CLTU043LO...
Date:10/7/2008
rg.
For this Initiative, IDRI is providing substantial expertise in
microbiology, molecular biology and chemistry, as well as managing the
Initiative's laboratory. IDRI serves as the principal coordinator for all
partnership efforts. C-LLY
(Logo: http://www.newscom.com/cgi-bin/prnh/20081007/CLTU043LOGO )
'/>"/>SOURCE Eli Lilly and Company Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 Related biology technology :1.
UPDATE: Free CME-certified Webcast: Opening the Door to Better Myocardial Infarction Outcomes: Emergency Departments Hold the Key2.
RG Global Corporate Update: First Coal Bed Methane Water Treatment Plant Near Completion; Expanding Water Treatment Applications3.
Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call4.
Update: HYSTA Announces Dr. Qi Lu to Continue on as President of HYSTA, USA5.
Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation6.
Lilly Declares Fourth-Quarter Dividend7.
Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar8.
Lilly and BioMS Medical Announce Global Licensing and Development Agreement9.
Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration10.
In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:11.
Lilly Announces Termination of AIR Insulin Program